A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
about
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A randomized, open-label, mult ...... ed non-small cell lung cancer.
@en
A randomized, open-label, mult ...... ed non-small cell lung cancer.
@nl
type
label
A randomized, open-label, mult ...... ed non-small cell lung cancer.
@en
A randomized, open-label, mult ...... ed non-small cell lung cancer.
@nl
prefLabel
A randomized, open-label, mult ...... ed non-small cell lung cancer.
@en
A randomized, open-label, mult ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
A randomized, open-label, mult ...... ced non-small cell lung cancer
@en
P2093
D R Spigel
H Nokihara
J C-H Yang
M Satouchi
N Iannotti
N Katakami
P2860
P304
P356
10.1093/ANNONC/MDX284
P577
2017-09-01T00:00:00Z